Novo Nordisk A/S (NYSE:NVO) Position Trimmed by Capital Advisors Inc. OK

Capital Advisors Inc. OK lowered its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 93.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,524 shares of the company's stock after selling 83,172 shares during the quarter. Capital Advisors Inc. OK's holdings in Novo Nordisk A/S were worth $572,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Jennison Associates LLC grew its position in Novo Nordisk A/S by 100.3% during the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company's stock valued at $2,129,761,000 after buying an additional 11,727,507 shares during the period. FMR LLC lifted its holdings in Novo Nordisk A/S by 122.7% during the third quarter. FMR LLC now owns 12,077,501 shares of the company's stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares in the last quarter. Morgan Stanley lifted its holdings in Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company's stock valued at $838,021,000 after purchasing an additional 4,526,199 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in Novo Nordisk A/S by 91.7% during the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company's stock valued at $827,354,000 after purchasing an additional 4,350,862 shares in the last quarter. Finally, Polen Capital Management LLC purchased a new position in Novo Nordisk A/S during the third quarter valued at $718,995,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 0.7 %

Shares of NVO traded down $0.89 during trading on Friday, reaching $124.51. 3,343,015 shares of the company traded hands, compared to its average volume of 3,653,790. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The stock has a market cap of $558.74 billion, a PE ratio of 46.03, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The stock has a 50-day simple moving average of $125.93 and a 200-day simple moving average of $109.86. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion during the quarter, compared to analysts' expectations of $9.14 billion. On average, analysts anticipate that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a $0.664 dividend. This is an increase from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S's dividend payout ratio is 49.17%.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price objective on the stock. UBS Group began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a "neutral" rating on the stock. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday. They issued an "outperform" rating and a $163.00 price target on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, April 1st. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and an average target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.